RALEIGH — A Raleigh-based life science company raised $17.2 million in a private equity offering, according to a Securities and Exchange Commission filing.
Bryn Pharma LLC filed the form on Feb. 21. It did not disclose what it intended to do with the proceeds.
The company is owned and operated by Dr. David Dworaczyk, who is responsible for all aspects of the organization and directing the growth and success of the company. Bryn Pharma is producing an alternative to the EpiPen.
The company is developing and manufacturing an innovative needleless nasal solution for the administration of emergency epinephrine.
Bryn Pharma, formerly Epi-Now LLC, raised $9.2 million in securities sold to 72 investors, according to a 2018 filing with the SEC.
Companies relying on a Reg D exemption do not have to register their offering of securities with the SEC, but they must file what’s known as a Form D electronically with the SEC after they first sell their securities.
The filing can be found online.
This story is from the North Carolina Business News Wire, a service of the UNC-Chapel Hill School of Media and Journalism
